Purchase Order 75N91023P00569
Award Date 8/1/23
Potential Completion Date 7/31/24
Potential Value $131K
Federal Agency
Awardee
Ultimate Awardee
Not listed Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Bethesda, MD 20892, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The National Cancer Institute (NCI), a component of the National Institutes of Health under the Department of Health and Human Services, awarded a $67,824 firm fixed-price purchase order to Illumina, Inc. for preventive maintenance, emergency service, support, and coverage of a government-owned Illumina NovaSeq 6000 sequencing system located at the NCI's Center for Cancer Research facility in San Diego, California. The contract, awarded on May 1, 2021, with a completion date of April 30, 2022,...
- The National Cancer Institute awarded a $256,545 firm fixed-price purchase order to Illumina, Inc. for preventive maintenance and ongoing service support of a government-owned Illumina NextSeq 2000 desktop sequencer (Serial Number: VH00760) located in San Diego, California. This contract represents Option Period Three of a multi-year maintenance agreement, with the current option period value reduced by $4,575. The contract will remain in effect through June 11, 2028, and requires qualified...
- The National Cancer Institute awarded a $735,959 firm fixed-price purchase order to Illumina, Inc. on March 18, 2024, for preventive maintenance and emergency repair services supporting a government-owned Illumina NovaSeq 6000 sequencing system at the National Institutes of Health Clinical Center in Bethesda, Maryland. The contract encompasses a one-year base period (March 2024 through March 2025) and includes four one-year option periods, extending through March 2029. Services include annual...
- This firm fixed-price purchase order contract was awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Illumina, Inc. for maintenance services on a government-owned Illumina NovaSeq 6000 sequencing instrument. The $134,247.36 contract provides annual preventive maintenance, emergency repair, software/firmware updates, replacement parts, and technical support for the sequencing system located at the NCI's Laboratory of Pathology in Bethesda,...
- The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a $22,646 purchase order to Illumina, Inc. for service agreement on a NovaSeq 6000 sequencer. The firm fixed price contract runs from December 1, 2023 through January 17, 2024 and will be performed in Rockville, Maryland. This purchase order provides sequencing services utilizing Illumina's NovaSeq 6000 platform to support the National Cancer Institute's cancer research efforts. No major...
- The National Cancer Institute within the National Institutes of Health awarded a $589,617.13 firm fixed-price purchase order to Illumina, Inc. on September 1, 2021, for maintenance services supporting genomic sequencing equipment at its Bethesda, Maryland facility. The contract covers preventative maintenance and emergency support for seven Illumina sequencers and associated instrumentation used by the NCI's Genetics Branch to advance cancer research and genomic analysis capabilities. This award...
- Illumina, Inc. was awarded a firm fixed price purchase order valued at $21,185.28 by the Department of Health and Human Services' National Institutes of Health National Cancer Institute. The contract is for bridge maintenance services to be performed at the agency's location in Bethesda, Maryland, with no set-aside designation applied. As a manufacturer and provider of sequencing and array-based solutions, Illumina will likely supply routine maintenance and support for genomic sequencing...
- This firm fixed-price purchase order was awarded by the Department of Health and Human Services' National Institutes of Health National Cancer Institute to Illumina, Inc., a manufacturer of genetic sequencing systems and solutions, for preventive maintenance, emergency service, and support for a government-owned Illumina NovaSeq 6000 Sequencing System. The contract has a period of performance from August 1, 2022 to July 31, 2023 and a potential value of $119,523.28. The requirement was...
- The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a $20,381.70 firm fixed price purchase order to Illumina, Inc. for unspecified products or services. The place of performance will be in Bethesda, Maryland through September 2023. Illumina will deliver the requested items or work to support the National Cancer Institute, part of the NIH focused on cancer research, treatment, and initiatives to reduce the public health burden of cancer....
- The National Cancer Institute (NCI) within the National Institutes of Health (NIH) awarded a $205,376.00 firm fixed price purchase order to Illumina, Inc. for maintenance services for a government-owned Illumina NextSeq 2000 sequencing system. The base period runs from February 1, 2024 through January 31, 2028, with the potential for three one-year extensions. The contract provides for annual preventative maintenance, remote technical support, and on-site emergency repairs within two business...